New Data for KEYTRUDA ® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three separate studies evaluating the use
of KEYTRUDA < sup > ® < /sup > (pembrolizumab), the company ’s anti-PD-1
therapy, in combination with other treatment regimens including
talimogene laherparepvec, dabrafenib plus trametinib, or low-dose
ipilimumab in patients with advanced melanoma. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-contact-html field-fieldpressreleasecontacthtml " > < div class= " field-label " > Contact: < /div > < div class= " field-items " > < div class= " field-item odd " > < p > Merck < br / > Media Contacts: < br / > Pamela Eisele, 267-305-3558 < br / > or < br / > An Phan, 908-255-6325 < br / > or < br / > I...

Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news